MAPT and Parkinson disease: Future studies with larger sample sizes and additional biomarkers, such as tau or amyloid pathology, may help clarify whether α-syn SAA negative sporadic PD represents a distinct PD subtype or are a result of technical limitations in the sensitivity of the assay.